Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Journal of Clinical Oncology

• Publication date

  1997-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.1997.15.6.2432PMID 9196159
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Critical factors for optimizing the 5-fluorouracil-folinic acid association in cancer chemotherapy.

  1996cited by this paper
• Adjuvant therapy of colon cancer.

  1995cited by this paper
• Combined intraperitoneal plus intravenous chemotherapy after curative resection for colonic adenocarcinoma.

  1995cited by this paper
• Adjuvant chemotherapy for colon and rectal cancer.

  1995cited by this paper
• Efficacy of adjuvant fluorouracil and folinic acid in colon cancer

  1995cited by this paper
• Levamisole adds granulocyte toxicity to 5FU-based chemotherapies in adjuvant treatment of Dukes B-C colorectal cancer. A preliminary report.

  1995cited by this paper
• Adjuvant Chemotherapy for Colon and Rectal Cancer.

  1995cited by this paper
• Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer.

  1995cited by this paper
• Role of adjuvant therapy in surgically resected colorectal carcinoma.

  1995cited by this paper
• [Fixed pigmented erythema caused by levamisole administration].

  1994cited by this paper
• Cerebral demyelination with 5-fluorouracil and levamisole.

  1994cited by this paper
• Adjuvant therapy for gastrointestinal cancer.

  1994cited by this paper
• Late mortality and levamisole adjuvant therapy in colorectal cancer.

  1994cited by this paper
• Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer.

  1994cited by this paper
• Preclinical and clinical aspects of biomodulation of 5-fluorouracil.

  1994cited by this paper
• The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03.

  1993cited by this paper
• Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy.

  1993cited by this paper
• Recent advances in the treatment of advanced colorectal cancer

  1993cited by this paper
• Neoadjuvant therapy for gastrointestinal cancers.

  1993cited by this paper
• Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma.

  1992cited by this paper
• Control of chemotherapy-induced diarrhoea with octreotide in patients receiving 5-fluorouracil.

  1992cited by this paper
• Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project.

  1992cited by this paper
• The inhibition of tumor growth by tumor mass.

  1991cited by this paper
• Drug treatment of colorectal cancer. Current status.

  1991cited by this paper
• Modulation of fluoropyrimidines by leucovorin: Rational and status

  1991cited by this paper
• Rational basis for the metabolic modulation of 5‐fluorouracil by leucovorin and interferon alpha

  1991cited by this paper
• Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.

  1990cited by this paper
• Relationship between dose rate of [6RS]Leucovorin administration, plasma concentrations of reduced folates, and pools of 5,10-methylenetetrahydrofolates and tetrahydrofolates in human colon adenocarcinoma xenografts.

  1990cited by this paper
• Enhancement of the antitumor effects of 5-fluorouracil by folinic acid.

  1990cited by this paper
• Influence of dose of [6RS]leucovorin on reduced folate pools and 5-fluorouracil-mediated thymidylate synthase inhibition in human colon adenocarcinoma xenografts.

  1990cited by this paper
• Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02.

  1990cited by this paper
• Adjuvant portal liver infusion in colorectal cancer with 5‐fluorouracil/heparin versus urokinase versus control results of a prospective randomized clinical trial (colorectal adenocarcinoma trial I)

  1990cited by this paper
• Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human colorectal carcinoma cell lines.

  1988cited by this paper
• In vivo potentiation of 5-fluorouracil by leucovorin in murine colon carcinoma.

  1988cited by this paper
• Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid.

  1986cited by this paper
• A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer

  1985cited by this paper
• 5-Fluorouracil incorporation in DNA of human breast carcinoma cells.

  1982cited by this paper
• Adjuvant chemotherapy in cancer of the colon and rectum: demonstration of effectiveness of prolonged 5-FU chemotherapy in a prospectively controlled, randomized trial.

  1981cited by this paper
• Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice.

  1981cited by this paper
• The scientific basis for adjuvant chemotherapy.

  1981cited by this paper
• Chemotherapy as an adjuvant to surgery for colorectal cancer. A follow-up report.

  1978cited by this paper
• Cytotoxicity of 5-fluoro-2'-deoxyuridine: requirement for reduced folate cofactors and antagonism by methotrexate.

  1978cited by this paper
• Intraluminal fluorouracil chemotherapy adjunct to surgical procedures for respectable carcinoma of the colon and rectum.

  1977cited by this paper
• Adjuvant chemotherapy in the surgical treatment of large bowel cancer

  1976cited by this paper
• Chemotherapy as an Adjuvant to Surgery for Colorectal Cancer

  1975cited by this paper
• Fudr as an adjuvant to surgery in cancer of the large bowel

  1973cited by this paper
• Fluorouracil as an adjuvant to surgery in carcinoma of the colon.

  1971cited by this paper
• Fluorinated Pyrimidines, A New Class of Tumour-Inhibitory Compounds

  1957cited by this paper

• Microbial vitamin biosynthesis links gut microbiota dynamics to chemotherapy toxicity

  2025cites this paper
• Beyond Chemotherapy: Exploring 5-FU Resistance and Stemness in Colorectal Cancer.

  2025cites this paper
• Metagenomic analysis during capecitabine therapy reveals microbial chemoprotective mechanisms and predicts drug toxicity in colorectal cancer patients

  2024cites this paper
• Dirhodium-Catalyzed Transannulation of N-Sulfonyl-1,2,3-triazoles to 2,3-Dehydropiperazines.

  2023cites this paper
• EpCAM aptamer activated 5-FU-loaded PLGA nanoparticles in CRC treatment; in vitro and in vivo study

  2022cites this paper
• Signaling Pathways Involved in 5-FU Drug Resistance in Cancer

  2022cites this paper
• Folate Receptor as a Biomarker and Therapeutic Target in Solid Tumors.

  2022cites this paper
• A bayesian approach to model the underlying predictors of early recurrence and postoperative death in patients with colorectal Cancer

  2022cites this paper
• Regulation of thymidylate synthase: an approach to overcome 5-FU resistance in colorectal cancer

  2022cites this paper
• Association Between Chemotherapy and Survival in T1 Colon Cancer With Lymph Node Metastasis: A Propensity-Score Matched Analysis

  2021cites this paper
• Pharmacogenomics of 5-fluorouracil in colorectal cancer: review and update

  2020cites this paper
• Pharmacogenomics of 5-fluorouracil in colorectal cancer: review and update

  2020cites this paper
• Gastrointestinal Cancers: Colorectal Cancer

  2019cites this paper
• SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer

  2018cites this paper
• Disparities in Colon Cancer Survival by Insurance Type: A Population-Based Analysis

  2018cites this paper
• Pharmacogenomics DNA Biomarkers in Colorectal Cancer: Current Update

  2017cites this paper
• Oral versus intravenous fluoropyrimidines for colorectal cancer.

  2017cites this paper
• Inhibition of uracil DNA glycosylase sensitizes cancer cells to 5-fluorodeoxyuridine through replication fork collapse-induced DNA damage

  2016cites this paper
• How folate metabolism affects colorectal cancer development and treatment; a story of heterogeneity and pleiotropy.

  2015cites this paper
• The Prognostic Value of the Primary Tumor's Nodal Status after Surgery for Colorectal Liver Metastases in the Era of Effective Systemic Therapy

  2015cites this paper
• Adjuvant Chemotherapy for T1 Node-Positive Colon Cancers Provides Significant Survival Benefit

  2014cites this paper
• Evaluating Predictive Pharmacogenetic Signatures of Adverse Events in Colorectal Cancer Patients Treated with Fluoropyrimidines

  2013cites this paper
• Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history.

  2013cites this paper
• Adjuvant colon cancer chemotherapy: Is there an Indian standard of care?

  2013cites this paper
• Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581.

  2011cites this paper
• Lymph node ratio is a powerful prognostic index in patients with stage III distal rectal cancer: a Japanese multicenter study

  2011cites this paper
• Chapter 24 – The Colon and Rectum

  2010cites this paper
• Safety and tolerability of FOLFOX4 in the adjuvant treatment of colon cancer in Asian patients: The MASCOT study

  2009cites this paper
• Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis.

  2008cites this paper
• Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1).

  2008cites this paper
• Colorectal cancer: from epidemiology to current treatment

  2006cites this paper
• Distribution of lymph node metastasis is a prognostic index in patients with stage III colon cancer.

  2006cites this paper
• Randomized trial of the efficacy of adjuvant chemotherapy for colon cancer with combination therapy incorporating the oral pyrimidine 1-hexylcarbamoyl-5-fluorouracil

  2006cites this paper
• [Adjuvant treatment of colon cancer MOSAIC study's main results].

  2006cites this paper
• Adjuvant treatment of colon cancer

  2005cites this paper
• Leucovorin and 5-fluorouracil versus levamisole and 5-fluorouracil as adjuvant chemotherapy in rectal cancer.

  2005cites this paper
• Gene Expression Profiling of Nonneoplastic Mucosa May Predict Clinical Outcome of Colon Cancer Patients

  2005cites this paper
• Maintenance Therapy to Suppress Micrometastasis: The New Challenge for Adjuvant Cancer Treatment

  2005cites this paper
• (Neo-)adjuvant treatments in colorectal cancer.

  2005cites this paper
• Maintenance Therapy to SuppressMicrometastasis : The NewChallenge forAdjuvant Cancer Treatment

  2005cites this paper
• Heterodinucleoside phosphates of 5-fluorodeoxyuridine and arabinofuranosylcytosine--new drugs in cancer chemotherapy?

  2005cites this paper
• Severe chemotherapy-induced diarrhea in patients with colorectal cancer: a cost of illness analysis

  2005influential citation
• Current controversies in the adjuvant therapy of colon cancer.

  2004cites this paper
• Adjuvant therapy for stage II colon cancer: an elephant in the living room?

  2004cites this paper
• Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

  2004cites this paper
• Randomized controlled trial of the efficacy of adjuvant immunochemotherapy and adjuvant chemotherapy for colorectal cancer, using different combinations of the intracutaneous streptococcal preparation OK-432 and the oral pyrimidines 1-hexylcarbamoyl-5-fluorouracil and uracil/tegafur

  2004cites this paper
• Leucovorin and fluorouracil vs levamisole and fluorouracil as adjuvant chemotherapy in rectal cancer.

  2004cites this paper
• Tumor dihydropyrimidine dehydrogenase in stage II and III colorectal cancer: low level expression is a beneficial marker in oral-adjuvant chemotherapy, but is also a predictor for poor prognosis in patients treated with curative surgery alone.

  2004cites this paper
• Randomized comparative study of surgical adjuvant chemotherapy using 5‐fluorouracil and dl‐leucovorin with CDDP, 5‐FU and dl‐leucovorin for advanced colorectal cancer

  2004cites this paper
• A COOPERATION MODEL OF CHEMOTHERAPY FOR COLORECTAL CANCER BETWEEN THE CLINIC AND A GENERAL HOSPITAL

  2004cites this paper
• Clinical research in pancreatic cancer: the Radiation Therapy Oncology Group trials.

  2003cites this paper
• 5,10-methenyltetrahydrofolate cyclohydrolase, rat liver and chemically catalysed formation of 5-formyltetrahydrofolate.

  2003cites this paper
• Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer.

  2003cites this paper
• Limited sampling model for the analysis of 5‐fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer

  2002cites this paper
• Angiogenesis inhibitor TNP-470 suppresses growth of peritoneal disseminating foci of human colon cancer line Lovo.

  2002cites this paper
• Relationship Between Plasma Concentrations of 5-Fluorouracil and 5-Fluoro-5,6-Dihydrouracil and Toxicity of 5-Fluorouracil Infusions in Cancer Patients

  2002cites this paper
• High-performance liquid chromatographic method for determination of leucovorin in plasma: validation and application to a pharmacokinetic study in healthy volunteers.

  2002cites this paper
• Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01.

  2001cites this paper
• Fatigue during preoperative chemoradiation for resectable rectal cancer

  2001cites this paper
• Fluorouracil P lus L eucovorin a s E ffective A djuvant Chemotherapy i n C uratively R esected S tage I II C olon Cancer: R esults o f t he T rial a djCCA-01

  2001cites this paper
• In vitro and in vivo inhibition of myeloperoxidase with 5-fluorouracil

  2001cites this paper
• Treatment of surgical patients is evidence-based.

  2001cites this paper
• p53 nuclear accumulation and multiploidy are adverse prognostic factors in surgically resected stage II colorectal cancers independent of fluorouracil-based adjuvant therapy.

  2001cites this paper
• Il Trattamento Adiuvante Del Carcinoma Del Colon

  2000cites this paper
• Achievements and future of chemotherapy.

  2000cites this paper
• Adjuvant Radio-Chemotherapy with 5-Fluorouracil and Leucovorin in Stage II and III Rectal Cancer: 12 Months vs. 6 Months of Therapy. A Study of the Association for Medical Oncology of the German Cancer Society

  2000cites this paper
• Factors influencing treatment decisions for patients with colorectal cancer.

  2000cites this paper
• Fluorouracil and Leucovorin with or without Interferon Alfa-2a as Adjuvant Treatment, in Patients with High-Risk Colon Cancer

  2000cites this paper
• Impact of the simultaneous administration of the (+)- and (−)-forms of formyl-tetrahydrofolic acid on plasma and intracellular pharmacokinetics of (−)-tetrahydrofolic acid

  2000cites this paper
• [Adjuvant treatment of carcinoma of the colon].

  2000cites this paper
• A novel, orally administered nucleoside analogue, OGT 719, inhibits the liver invasive growth of a human colorectal tumor, C170HM2.

  1999cites this paper
• Trattamento Adiuvante del Carcinoma del Colon Stato Dell'arte e Prospettive Future

  1999cites this paper
• Is there a standard chemotherapeutic strategy in colorectal cancer?

  1999cites this paper
• [Fundamentals and results of cytostatic chemotherapy in some of the most common solid tumors].

  1999cites this paper
• Marked variation of thymidylate synthase and folylpolyglutamate synthetase gene expression in human colorectal tumors.

  1999cites this paper
• [Adjuvant therapy of colon cancer. State of the art and future perspectives].

  1999cites this paper
• Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer.

  1999cites this paper
• Adjuvant therapy for pancreatic cancer: back to the future.

  1998cites this paper
• Nuovi Orientamenti Nel Trattamento Chemioterapico Delle Neoplasie Del Grosso Intestino: Punti Fermi E Promesse

  1998cites this paper
• GIVIO‐SITAC 01

  1998cites this paper
• Overwhelming 5-fluorouracil toxicity in patients whose diabetes is poorly controlled.

  1998cites this paper
• Phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent adenocarcinoma of the cervix: a Gynecologic Oncology Group study.

  1997cites this paper